All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The National Comprehensive Cancer Network (NCCN) has published guidelines for pediatric patients with Hodgkin lymphoma and their families; the guidelines provide a clear explanation of all aspects of the disease, including:
The book will also feature organizations and contacts to connect families and provide personalized support for every step of the decision process.
NCCN guidelines are evidence-based recommendations developed by a panel of experts from leading NCCN Member Institutions, they are frequently updated and contain detailed clinical practice recommendations for several cancer types. These new guidelines are aimed at pediatric patients diagnosed with Hodgkin lymphoma and their caregivers. They include,
As pediatric Hodgkin lymphoma is a rare cancer, this guide will disseminate peer-reviewed guidance that patients and families can refer to for accurate, accessible information.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox